Results 281 to 290 of about 392,718 (341)

Synovial Fluid‐derived Micrococcus Luteus G18 Exacerbates Osteoarthritis Progression by Promoting Chondrocyte Degradation via TLR2/JNK/AP‐1 Signaling Pathway

open access: yesAdvanced Science, EarlyView.
Traditionally considered sterile, the articular cavity is now recognized to harbor microbial communities influencing osteoarthritis (OA). Integrating 16S rRNA sequencing and culturomics, Micrococcus luteus is enriched in advanced OA. Notably, M. luteus G18 exacerbates cartilage degeneration via TLR2/JNK/AP‐1‐mediated ECM disruption, revealing intra ...
Tingtao Chen   +6 more
wiley   +1 more source

A Novel CYP2E1 Inhibitor, 4‐Methyl‐5‐Acetylthiazole (Q11), Alleviates Obesity Via Modulating Adipose Inflammation and Mitochondrial Dysfunction

open access: yesAdvanced Science, EarlyView.
Obesity involves chronic inflammation and mitochondrial dysfunction. This study identifies cytochrome P450 2E1 (CYP2E1) as a novel inflammatory target in adipose tissue. Its activity increases in obese mice and correlates with inflammation and mitochondrial impairment.
Jinhuan Qiu   +10 more
wiley   +1 more source

Small extracellular vesicle cargo as biomarkers in autoimmune rheumatic diseases: a systematic review. [PDF]

open access: yesRheumatol Int
Chatzopoulos MK   +5 more
europepmc   +1 more source

Esketamine/Ketamine: Dual‐Action Mechanisms and Clinical Prospects beyond Anesthesia in Psychiatry, Immunology, and Oncology

open access: yesAdvanced Science, EarlyView.
Esketamine and ketamine are widely used for perioperative analgesia and anesthesia. Despite their established roles in analgesia, sedation, and anesthesia, as well as emerging antidepressant, anti‐tumor, and anti‐inflammatory effects, their clinical use is limited due to side effects and addiction potential.
Yinxin Wang   +7 more
wiley   +1 more source

Sarcopenia in Rheumatic Diseases: A Hidden Issue of Concern. [PDF]

open access: yesDiseases
Pardali EC   +8 more
europepmc   +1 more source

Nanozyme‐Integrated Hydrogel Targeting AGEs for Diabetic Osteoarthritis Therapy

open access: yesAdvanced Science, EarlyView.
A nanozyme–integrated hydrogel (PTC‐MP) exhibiting with mild photothermal effects is constructed, and a “3R” (restrain‐restore‐reinforce) strategy is proposed for diabetic osteoarthritis (DOA) treatment based on advanced glycation end products (AGEs) targeting.
Rui Chen   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy